



December 18, 2023

Nevada Medicaid Web Announcement 3241

COVID-19 UNWIND: COVID-19 Administration and Vaccine Procedure Code Emergency Use Authorization and Revocation Updates

The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the COVID-19 vaccine administration and vaccine procedure codes listed in Table 1 below effective with dates of service on or after September 11, 2023. Prior authorization is not required.

The procedure codes and descriptions of the procedure codes are shown below.

Table 1.

Procedure Code	Description
90480	ADMN SARSCOV2 VACC 1 DOSE
91318	Pfizer SARSCOV2 VAC 3MCG TRS-SUC
91319	Pfizer SARSCV2 VAC 10MCG TRS-SUC IM
91320	Pfizer SARSCV2 VAC 30MCG TRS-SUC IM
91321	Moderna SARSCOV2 VAC 25 MCG/.25ML IM
91322	Moderna SARSCOV2 VAC 50 MCG/0.5ML IM

The following provider types may bill the procedure codes listed in Table 1:

Table 2.

Provider Type	Provider Type Description
12	Hospital, Outpatient
17 specialty 166	Special Clinics: Family Planning
17 specialty 174	Special Clinics: Public Health Clinic
17 specialty 179	Special Clinics: School Based Health Centers (SBHC)
17 specialty 180*	Special Clinics: Rural Health Clinic
17 specialty 181*	Special Clinics: Federally Qualified Health Center (FQHC)
17 specialty 182*	Special Clinics: Indian Health Program
17 specialty 195	Special Clinics: Community Health Clinic, State Health Division
17 specialty 198	Special Clinics: Human Immunodeficiency Virus (HIV)
20	Physician, M.D., Osteopath, D.O.
24	Advanced Practice Registered Nurse (APRN)
32 specialty 249	Community Paramedicine
47*	Indian Health Services (IHS) and Tribal Clinics
60	School Health Services
74	Nurse Midwife
77	Physician's Assistant

*PT 17 specialties 180, 181 and 182 and PT 47 providers must bill the vaccine administration codes with modifier Q2. The claim will pay according to the established encounter rate and the vaccine administration code will pay at \$0 as the service is included in the encounter reimbursement.

The FDA has issued an EUA revocation for the COVID-19 vaccine and administration procedure codes listed below. The following procedure codes are not authorized effective with dates of service on or after September 12, 2023.

Table 3.

Procedure Code	Description
91312	SARSCOV2 VAC BVL 30MCG/0.3ML
91313	SARSCOV2 VAC BVL 50MCG/0.5ML
91314	SARSCOV2 VAC BVL 25MCG/.25ML
91315	SARSCOV2 VAC BVL 10MCG/0.2ML
91316	CORONAVIRUS VACCINE 17
91317	CORONAVIRUS VACCINE 18
0121A	FEE COVID-19 VAC 13 RES
0124A	ADM SARSCV2 BVL 30MCG/.3ML B
0134A	ADM SARSCV2 BVL 50MCG/.5ML B
0141A	FEE COVID-19 VAC 15 RES
0142A	FEE COVID-19 VAC 15 RES
0144A	ADM SRSCV2 BVL 25MCG/.25ML B
0151A	FEE COVID-19 VAC 16 RES
0154A	ADM SARSCV2 BVL 10MCG/.2ML B
0164A	FEE COVID-19 VAC 17 RES
0171A	FEE COVID-19 VAC 18 RES
0172A	FEE COVID-19 VAC 18 RES
0173A	FEE COVID-19 VAC 18 RES
0174A	FEE COVID-19 VAC 18 RES

Claims for the procedure codes in Table 1 that denied and claims for the procedure codes in Table 3 that paid may be reprocessed automatically at a later date. A future web announcement will notify providers of the details of any claim reprocessing efforts.

When claims are reprocessed, please be aware that all system and clinical claim editor edits are applicable. As a result, there may be no additional payment, and other claim denials may be received. Providers have the right to appeal denied claims, including those denied upon reprocessing. Please refer to [Medicaid Services Manual Chapter 100](#) and the [Billing Manual](#) for information concerning the claim appeal process and time frames.